MedTrace Logo

Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases

NCT06396871 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2024-05-02

No results posted yet for this study

Summary

The goal of this cross-sectional observational study is to to perform a thorough characterization of the quantitative and qualitative differences in peripheral blood cells, and circulating factors (proteins, metabolites, lipids, extracellular vesicles) in different stages of several metabolic diseases (diabetes, obesity, non-alcoholic fatty liver disease) that share common pathophysiological mechanisms and in comparison with adult healthy controls. The main question\[s\] it aims to answer are:

* Which are the quantitative (number and concentration) and qualtitative (characteristics, functional assays) differences in platelets in patients with metabolic diseases vs subjects without metabolic diseases
* Which are the quantitative (number and concentration) and qualtitative (characteristics, functional assays) differences in leucocytes or circulating molecules in patients with metabolic diseases vs subjects without metabolic diseases

Conditions

Interventions

DIAGNOSTIC_TEST

Oral glucose tolerance test

75g of a standardized glucose solution followed by blood draw at 0, 30, 60, 90, 120 min

DIAGNOSTIC_TEST

Liver Ultrasound

A crude assessment of liver status in order to identify the presence of steatosis or not will take place with ultrasound.

DIAGNOSTIC_TEST

Fibroscan of the Liver

FibroScan non-invasively measures the stiffness of the liver by capturing and calculating the speed of a shear wave as it travels through the liver (vibration controlled transient elastography).

DIAGNOSTIC_TEST

Magentic Resonance Imaging (MRI) of the liver

The exact calculation of liver fat with proton density fat fraction will take place with MRI.

Sponsors & Collaborators

  • Technische Universität Dresden

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-16
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06396871 on ClinicalTrials.gov